Synergistic Mechanism of Interferon alpha-1b, Interleukin-2 and Thalidomide for Immune Regulation in Patients with Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2021.01.004
- Author:
Rui-Hua MI
1
;
Lin CHEN
1
;
Ya-Lan ZHOU
1
;
Dong-Bei LI
1
;
Sha LIU
1
;
Xiao-Jiao WANG
1
;
Jia LIU
1
;
Min-Fang WANG
2
;
Xiao-Miao MA
2
;
Zhi-Chun LI
3
;
Hong-Mian ZHAO
4
;
Yu-Lin XU
5
;
Shu-Xia CHEN
6
;
Hai-Ping YANG
7
;
Zhi-Qiang GUO
8
;
Chun-Lai LUAN
9
;
Shu-Li GUO
10
;
Qing-Lin SONG
11
;
Xu-Dong WEI
12
Author Information
1. Cancer Hospital Affiliated to Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China.
2. Pingdingshan First People's Hospital, Pingdingshan 467000, Henan Province, China.
3. Puyang City People's Hospital, Puyang 457000, Henan Province, China.
4. Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China.
5. 989th,Hospital of PLA, Luoyang 471000, Henan Province, China.
6. Shangqiu city First People's Hospital, Shangqiu 476000, Henan Province, China.
7. First Affiliated Hospital of Science and Technology University of Henan, Luoyang 471000, Henan Province, China.
8. Central Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China.
9. Anyang District Hospital, Anyang 455000, Henan Province, China.
10. Central Hospital of Luoyang, Luoyang 471000, Henan Province, China.
11. Jiaozuo People's Hospital, Jiaozuo 454150, Henan Province, China.
12. Cancer Hospital Affiliated to Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China. E-mail:weixudong63@126.com.
- Publication Type:Journal Article
- MeSH:
CD8-Positive T-Lymphocytes;
Humans;
Interferon-alpha;
Interleukin-2;
Leukemia, Myeloid, Acute/drug therapy*;
Perforin;
Thalidomide
- From:
Journal of Experimental Hematology
2021;29(1):26-31
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the synergistic immunomodulatory mechanism of interferon alpha-1b, interleukin-2 and thalidomide (ITI) regimen on patients with acute myeloid leukemia (AML).
METHODS:Sixty eight untreated de novo or relapsed or refractory or maintenance therapy patients with AML admitted in the Affiliated Cancer Hospital of Zhengzhou University and the other 11 medical units from March 2016 to May 2019 were treated with ITI regimen. Peripheral blood specimen per patient was collected into EDTA-K3 anticoagulation vacuum tube before the administration of ITI and 3 months after the treatment; peripheral blood lymphocyte subsets and perforin and Granzyme B expression were analyzed by using flow cytometry; the levels of VEGF, IFN-γ, TNF-α and IL-6 in the plasma were detected by using a cytometric bead array. Thirty-five healthy subjects from the hospital physical examination centre were selected as normal controls.
RESULTS:The ratio of CD4
CONCLUSION:The ITI regimen can raise the ratio of CD4
